NCT07197580 - Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

February 28, 2029

Conditions

ccRCCRenal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)Renal Cell Cancer MetastaticRenal Cell Cancer, RecurrentClear Cell Renal Cell Cancer (ccRCC)

Interventions

RADIATION

177Lu-TLX250

3 infusions of 177Lu-TLX250 at 8-week intervals or 6 infusions 177Lu-TLX250 at 4-week intervals

Trial Locations (3)

3051

Melbourne Theranostic Innovation Centre (MTIC), Melbourne N.

3084

Austin Health, Heidelberg

6150

GenesisCare, Fiona Stanley Hospital (Murdoch), Murdoch